BCR_ABL1, Female African doctor talking to female patient
Oncology | Blood Cancer

BCR::ABL1 Mbcr testing, whenever you need it

Offer oncologist-hematologists consistency in CML monitoring

BCR::ABL1 Mbcr fusion gene in CML monitoring

More than 95% of chronic myeloid leukemia (CML) cases have the BCR::ABL1 fusion gene.

Measuring BCR::ABL1 Mbcr levels enables oncologist-hematologists monitor CML effectively and make better informed management decisions. With the International Scale (IS) standardization of BCR::ABL1 Mbcr measurements, all providers on the patient journey can be sure they’re on the same page. BCR::ABL1 Mbcr testing also helps researchers advance CML clinical research.

More about CML
Two scientists working in a laboratory, focused on pipetting, Clinical Genomics
BCR::ABL1, International Scale

Reliably quantify BCR::ABL1 Mbcr transcripts

Our solutions let you reliably detect and quantify BCR::ABL1 Mbcr levels directly to the WHO International Scale (IS).

With the BCR::ABL1 Mbcr testing kits, you can be sure of:

  • Reliable quantitative detection of BCR::ABL1 Mbcr e14a2 (b3a2) & e13a2 (b2a2)  fusion gene transcripts
  • Direct results alignment on the international scale in every run and reporting molecular response status
  • Inter-lab harmonization in CML monitoring
  • Consistent results and increased lab efficiency
  • An Integrated, ready-to-use workflow that saves time and lowers costs

IS-standardized testing with ipsogen BCR::ABL1 Mbcr kits

The ipsogen BCR-ABL1 Mbcr IS-MMR and ipsogen BCR-ABL1 Mbcr RGQ RT-PCR kits let you accurately monitor the molecular response on the established WHO IS in patients diagnosed with Ph+ CML.

With the kits, you get:

  • Quantitative measurement of the BCR::ABL1 Mbcr fusion gene e14a2 (b3a2) & e13a2 (b2a2) transcripts in total RNA extracted from whole blood
  • Direct conversion of results in every run to the established World Health Organization (WHO) IS and reporting of molecular response status

Browse our region-specific BCR::ABL1 Mbcr tests

In line with established HUGO Gene Nomenclature Committee (HGNC) recommendations for the fusion gene nomenclature (Bruford EA, et al. Leukemia. 2021, https://doi.org/10.1038/s41375-021-01436-6), we are implementing use of italics and double colon (::) for fusion genes designation (e.g. BCR::ABL1). However historical nomenclature (e.g. BCR-ABL1) may persist in our materials.